Phase
Condition
Fabry Disease
Kidney Disease
Treatment
AMT-191
Clinical Study ID
Ages 18-50 Male
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Male of age ≥ 18 years and ≤50 years
Confirmed clinical diagnosis of classic Fabry disease (FD) defined as:
Absent or minimal αGAL A enzyme activity < 1% of mean normal (Vardarli, 2020)measured in isolated peripheral leukocytes regardless of variant status; OR
Galactosidase A gene (GLA) pathogenic or likely pathogenic variant associatedwith classic FD phenotype identified on molecular genetic testing
eGFR ≥ 40 mL/min/1.73 m2
Participant agrees to use a condom during sexual intercourse until semen sheddingsamples have tested negative at 3 consecutive visits (expected not to exceed aperiod of 18 months)
Suboptimal response after at least 12 months* of enzyme replacement therapy (ERT)treatment. Suboptimal response is defined as plasma lyso-Gb3 ≥ 2.3 nanograms permilliliter (ng/mL) at Screening and one or both of the following:
Persistent moderate or severe neuropathic pain (intermittent or continuous)over a period of at least 3 months prior to consent
Presence of gastrointestinal symptoms (abdominal cramping, constipation, ordiarrhea), reported by the Participant as moderate or severe and that areeither persistent or occurring two or more times over the 12 weeks prior toconsent *Note: Timing of 12 months is counted from the first ERT treatment tothe most recent ERT treatment. The appropriateness of the schedule and numberof doses received during that period is determined by the treating physicianand is not defined by this study. However, none of the regularly scheduleddoses in the patient's established dosing schedule should have been skipped inthe 3 months prior to the consent, to ensure consistent assessment of chronicpain and GI symptoms for eligibility.
Weight ≤ 120 kilograms (kg)
Able and willing to provide informed consent
Agrees to have no vaccinations within 6 weeks prior to and 6 weeks after dosing withAMT-191 unless allowed by study protocol
Exclusion
Exclusion Criteria:
Any allergic hypersensitivity reaction to ERT or infusion reaction in the 12 monthsprior to consent that was of severity grade 3 or above based on Common TerminologyCriteria for Adverse Events (CTCAE v5.0) and required emergency intervention forhypertension/hypotension to stabilize blood pressure or hypoxia OR any otherlife-threatening complication.
Proteinuria, with random urine protein/creatinine ratio (rUPCR) ≥1 mg/mg atScreening
Any previous treatment with investigational drug within 3 months prior to firstScreening assessment
Any previous treatment with gene therapy
Any anticipated participation in interventional studies for the treatment of FD
Current use of chaperone therapy such as migalastat (Galafold®)
Malignancy within 5 years of Screening, except for basal or squamous cell carcinomaof the skin
Positive serology test at Screening for hepatitis B surface antigen (HbsAg),hepatitis C antibody (HCAb), or human immunodeficiency virus (HIV), or active orlatent infection with tuberculosis (TB) measured by QuantiFERON test
Active or ongoing infection or any other significant concurrent, uncontrolledmedical condition including, but not limited to, renal, hepatic, cardiovascular,hematological, GI, endocrine (such as diabetes mellitus with poor glycemic control),pulmonary, neurological, cerebral, or psychiatric disease, alcoholism, drugdependency, or any other psychological disorder that could, in the opinion of theInvestigator, risk the safety of the Participant, or interfere with adherence to theprotocol procedures or interpretation of results
Evidence of any liver disease, including hepatitis, fibrosis, cirrhosis of theliver, neoplastic lesion, or any known medical condition that could impact theintended transduction of the vector and/or expression and activity of the protein
History of kidney transplantation or currently on hemodialysis or peritonealdialysis
Moderately severe to severe cardiovascular disease in the opinion of theInvestigator, New York Heart Association (NYHA) class 3 or 4 (see Appendix 2);history of stroke or transient ischemic attacks within the 12 months prior toScreening; history of ventricular tachycardia, history of or detection of othersignificant arrhythmia during Screening; significant thromboembolic disease history (eg, pulmonary embolism); or history of thrombotic risk resulting in current use ofanticoagulant/antiplatelet agents (not including prophylactic use of low-doseaspirin)
Uncontrolled hypertension, defined as systolic blood pressure >140 millimeters ofmercury (mmHg) (inclusive) and/or diastolic blood pressure outside the range of 60to 85 mmHg (inclusive) at Screening, confirmed on at least 2 repeated measurements
- Patients taking blood pressure medication to control blood pressure orproteinuria (eg, angiotensin-converting enzyme [ACE] inhibitors and angiotensinII receptor blockers [ARBs]) and have been titrated to a stable dose for atleast 3 months prior to Screening are allowed in the study.
Glycated hemoglobin (HbA1c) at Screening ≥7%
Contraindication to systemic corticosteroid therapy or immunosuppressive therapy
Chronic steroid use, defined as ≥ 3 months of oral corticosteroid use within the 12months prior to Screening
Known uncontrolled allergic conditions or Type I allergy/hypersensitivity to anycomponent of the AMT-191 excipients (not including infusion-related reactions toERT)
Screening laboratory values for renal and liver function that meet or exceed any ofthe following:
Alanine transaminase (ALT) > 2 x upper limit of normal for the testinglaboratory (ULN)
Aspartate aminotransferase (AST) > 2 x ULN
Total Bilirubin > 2 x ULN (except if this is caused by Gilbert disease)
Alkaline phosphatase (ALP) > 2 x ULN
Creatinine > 2 x ULN
Screening laboratory values for hematologic and coagulation function that meet anyof the following:
Hemoglobin < lower limit of normal (LLN) (as per reference laboratory ranges)
Platelet count < 150 x1000/μl
International normalized ratio (INR) >1.1
Soluble terminal complement complex (sC5b-9)>ULN
Significant anatomical abnormalities on renal ultrasound such as the presence ofonly 1 kidney, significant differences in kidney sizes between the right and leftkidneys >1.5 centimeters (about 0.59 inch), or presence of kidney cysts
Study Design
Study Description
Connect with a study center
The Kirklin Clinic Of university of Alabama Birmingham Hospital
Birmingham, Alabama 35233
United StatesActive - Recruiting
Emory University School of Medicine
Atlanta, Georgia 30322
United StatesActive - Recruiting
Ann & Robert H. Lurie Children's Hospital of Chicago
Chicago, Illinois 60611
United StatesActive - Recruiting
MHealth Fairview University of Minnesota Medical Center East Bank
Minneapolis, Minnesota 55455
United StatesActive - Recruiting
NYC Health + Hospitals/Metropolitan
New York, New York 10029
United StatesActive - Recruiting
UPMC Children's Hospital of Pittsburgh
Pittsburgh, Pennsylvania 15224
United StatesActive - Recruiting
University of Utah, Clinical and Translational Sciences Institute
Salt Lake City, Utah 84108
United StatesActive - Recruiting
Lysosomal & Rare Disorders Research and Treatment Center, Inc
Fairfax, Virginia 22030
United StatesActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.